BDX
Becton Dickinson and Company
NYSE: BDX · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$198.34
+1.63% today
Updated 2026-10-29
Market cap
$52.23B
P/E ratio
44.59
P/S ratio
2.32x
EPS (TTM)
$4.30
Dividend yield
2.16%
52W range
$124 – $196
Volume
1.7M
Becton Dickinson and Company (BDX) Insider transactions
Net insider activity
Net selling (284,569,588 shares)
Buy transactions
50
Sell transactions
49
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-09-28 | FELD, MICHAEL | EVP, Chief Revenue Officer | S | 76 | $183.70 | $13961.20 |
| 2026-09-02 | ROQUE, VITOR | EVP & Chief Financial Officer | Sale | 190 | — | — |
| 2026-08-26 | FELD, MICHAEL | EVP, Chief Revenue Officer | Sale | 165 | $188.49 | $31100.85 |
| 2026-08-20 | FELD, MICHAEL | EVP, Chief Revenue Officer | Sale | 1,049 | — | — |
| 2026-08-13 | POLEN, THOMAS E JR | Director, Chairman, CEO and President | Sale | 43,278 | — | — |
| 2026-08-13 | POLEN, THOMAS E JR | Director, Chairman, CEO and President | Buy | 43,278 | $167.25 | $7.24M |
| 2026-08-13 | POLEN, THOMAS E JR | Director, Chairman, CEO and President | Sale | 39,126 | $185.00 | $7.24M |
| 2026-08-13 | POLEN, THOMAS E JR | Director, Chairman, CEO and President | Sale | 4,152 | $185.00 | $768120.00 |
| 2026-08-11 | GOETTE, ROLAND | EVP and President, EMEA | Sale | 2,438 | $180.84 | $440887.92 |
| 2026-08-06 | HUFFINES, ROBERT LUTHER | Director | Buy | 189 | $165.62 | $31302.18 |
| 2026-08-06 | BYINGTON, CARRIE L | Director | Buy | 94 | $165.62 | $15568.28 |
| 2026-07-27 | FELD, MICHAEL | EVP, Chief Revenue Officer | Sale | 75 | $157.13 | $11784.75 |
| 2026-07-02 | MUHSIN, BILAL | EVP & President Connected Care | Sale | 1,935 | — | — |
| 2026-07-01 | MUHSIN, BILAL | EVP & President Connected Care | Buy | 14,342 | — | — |
| 2026-06-26 | FELD, MICHAEL | EVP, Chief Revenue Officer | Sale | 75 | $152.80 | $11460.00 |
| 2026-06-24 | GARRISON, MICHAEL DAVID | EVP & Pres Med.Essntl&BioPharm | Sale | 1,100 | $145.66 | $160226.00 |
| 2026-06-10 | GARRISON, MICHAEL DAVID | EVP & Pres Med.Essntl&BioPharm | Sale | 1,100 | $151.48 | $166628.00 |
| 2026-06-01 | POLEN, THOMAS E JR | Director, Chairman, CEO and President | Sale | 20,209 | — | — |
| 2026-06-01 | POLEN, THOMAS E JR | Director, Chairman, CEO and President | Buy | 20,209 | $126.16 | $2.55M |
| 2026-06-01 | POLEN, THOMAS E JR | Director, Chairman, CEO and President | Sale | 17,445 | $146.15 | $2.55M |
| 2026-06-01 | POLEN, THOMAS E JR | Director, Chairman, CEO and President | Sale | 2,764 | $146.35 | $404511.40 |
| 2026-06-01 | MENZIUSO, PETER | EVP and President, BDI | Buy | 14,258 | — | — |
| 2026-05-26 | FELD, MICHAEL | EVP, Chief Revenue Officer | Sale | 75 | $147.35 | $11051.25 |
| 2026-05-08 | HUFFINES, ROBERT LUTHER | Director | Buy | 210 | $149.04 | $31298.40 |
| 2026-05-08 | BYINGTON, CARRIE L | Director | Buy | 105 | $149.04 | $15649.20 |
| 2026-05-07 | ROQUE, VITOR | EVP & Chief Financial Officer | Buy | 1,721 | — | — |
| 2026-04-27 | FELD, MICHAEL | EVP, Chief Revenue Officer | Sale | 74 | $151.94 | $11243.56 |
| 2026-04-06 | NEAL, SHANA CAROL | EVP and Chief People Officer | Sale | 1,146 | — | — |
| 2026-03-26 | FELD, MICHAEL | EVP, Chief Revenue Officer | Sale | 75 | $156.83 | $11762.25 |
| 2026-03-16 | MINNIX, LANESHA | EVP and General Counsel | Buy | 7,492 | — | — |
| 2026-03-02 | SPIKNER, PAMELA L. | SVP Controller & CAO | Buy | 931 | — | — |
| 2026-03-02 | ROQUE, VITOR | Interim CFO | Buy | 931 | — | — |
| 2026-02-26 | FELD, MICHAEL | EVP, Chief Revenue Officer | Sale | 75 | $181.84 | $13638.00 |
| 2026-02-18 | SCOTT, BERTRAM L | Director | Sale | 953 | $182.61 | $174027.33 |
| 2026-02-09 | BECTON, DICKINSON & CO | 10% Owner | Sale | 284,771,350 | — | — |
| 2026-02-04 | JONES, CHRISTOPHER IAN MONTAGUE | Director | Buy | 272 | $201.91 | $54919.52 |
| 2026-02-04 | HUFFINES, ROBERT LUTHER | Director | Buy | 100 | $201.91 | $20191.00 |
| 2026-02-04 | BYINGTON, CARRIE L | Director | Buy | 30 | $201.91 | $6057.30 |
| 2026-01-27 | WRIGHT, JACQUELINE | Director | Buy | 1,098 | — | — |
| 2026-01-27 | WALDSTREICHER, JOANNE | Director | Buy | 1,098 | — | — |
| 2026-01-27 | SCOTT, BERTRAM L | Director | Buy | 1,098 | — | — |
| 2026-01-27 | RING, TIMOTHY M | Director | Buy | 1,098 | — | — |
| 2026-01-27 | JONES, CHRISTOPHER IAN MONTAGUE | Director | Buy | 1,098 | — | — |
| 2026-01-27 | HUFFINES, ROBERT LUTHER | Director | Buy | 1,098 | — | — |
| 2026-01-27 | HENDERSON, JEFFREY WILLIAM | Director | Buy | 1,098 | — | — |
| 2026-01-27 | HAYES, GREGORY | Director | Buy | 1,098 | — | — |
| 2026-01-27 | ECKERT, R ANDREW | Director | Buy | 1,098 | — | — |
| 2026-01-27 | BYINGTON, CARRIE L | Director | Buy | 1,098 | — | — |
| 2026-01-27 | BROWN, WILLIAM M | Director | Buy | 1,098 | — | — |
| 2026-01-26 | FELD, MICHAEL | EVP, CRO & Pres. Life Sciences | Sale | 75 | $202.73 | $15204.75 |
| 2026-01-21 | SPIKNER, PAMELA L. | SVP Controller & CAO | Sale | 84 | — | — |
| 2026-01-15 | GARRISON, MICHAEL DAVID | EVP & Pres Med.Essntl&BioPharm | Sale | 3,054 | — | — |
| 2026-01-15 | GARRISON, MICHAEL DAVID | EVP & Pres Med.Essntl&BioPharm | Buy | 3,054 | $167.91 | $512797.14 |
| 2026-01-15 | GARRISON, MICHAEL DAVID | EVP & Pres Med.Essntl&BioPharm | Sale | 2,454 | $209.00 | $512886.00 |
| 2026-01-15 | GARRISON, MICHAEL DAVID | EVP & Pres Med.Essntl&BioPharm | Sale | 1,010 | $206.54 | $208605.40 |
| 2026-01-15 | GARRISON, MICHAEL DAVID | EVP & Pres Med.Essntl&BioPharm | Sale | 600 | $209.00 | $125400.00 |
| 2026-01-03 | SHAN, DAVID | EVP and Chief ISC Officer | Sale | 44 | — | — |
| 2025-12-26 | FELD, MICHAEL | EVP, CRO & Pres. Life Sciences | Sale | 74 | $196.08 | $14509.92 |
| 2025-12-17 | GARRISON, MICHAEL DAVID | EVP & Pres Med.Essntl&BioPharm | Sale | 629 | $196.03 | $123302.87 |
| 2025-12-01 | WRIGHT, JACQUELINE | Director | Buy | 180 | — | — |
| 2025-12-01 | HUFFINES, ROBERT LUTHER | Director | Buy | 180 | — | — |
| 2025-12-01 | FELD, MICHAEL | EVP, CRO & Pres. Life Sciences | Sale | 75 | $193.36 | $14502.00 |
| 2025-11-26 | SPIKNER, PAMELA L. | SVPController & Chief Acct Off | Buy | 1,234 | — | — |
| 2025-11-26 | SHAN, DAVID | EVP and Chief ISC Officer | Buy | 3,504 | — | — |
| 2025-11-26 | SHAN, DAVID | EVP and Chief ISC Officer | Buy | 1,025 | — | — |
| 2025-11-26 | SHAN, DAVID | EVP and Chief ISC Officer | Sale | 134 | — | — |
| 2025-11-26 | POLEN, THOMAS E JR | Chairman, CEO and President | Buy | 165,581 | — | — |
| 2025-11-26 | POLEN, THOMAS E JR | Chairman, CEO and President | Buy | 22,521 | — | — |
| 2025-11-26 | POLEN, THOMAS E JR | Chairman, CEO and President | Sale | 17,421 | — | — |
| 2025-11-26 | NEAL, SHANA CAROL | EVP and Chief People Officer | Buy | 6,727 | — | — |
| 2025-11-26 | NEAL, SHANA CAROL | EVP and Chief People Officer | Buy | 3,525 | — | — |
| 2025-11-26 | NEAL, SHANA CAROL | EVP and Chief People Officer | Sale | 2,454 | — | — |
| 2025-11-26 | MUHSIN, BILAL | EVP & President Connected Care | Buy | 9,530 | — | — |
| 2025-11-26 | MOCHERLA, PAVAN KUMAR | EVP & President, Greater Asia | Buy | 2,208 | — | — |
| 2025-11-26 | MOCHERLA, PAVAN KUMAR | EVP & President, Greater Asia | Buy | 708 | — | — |
| 2025-11-26 | GOETTE, ROLAND | EVP and President, EMEA | Buy | 1,906 | — | — |
| 2025-11-26 | GOETTE, ROLAND | EVP and President, EMEA | Buy | 1,237 | — | — |
| 2025-11-26 | GOETTE, ROLAND | EVP and President, EMEA | Sale | 138 | — | — |
| 2025-11-26 | GARRISON, MICHAEL DAVID | EVP & Pres Med.Essntl&BioPharm | Buy | 7,568 | — | — |
| 2025-11-26 | GARRISON, MICHAEL DAVID | EVP & Pres Med.Essntl&BioPharm | Buy | 3,048 | — | — |
| 2025-11-26 | GARRISON, MICHAEL DAVID | EVP & Pres Med.Essntl&BioPharm | Sale | 1,769 | — | — |
| 2025-11-26 | FELD, MICHAEL | EVP, CRO & Pres. Life Sciences | Buy | 8,829 | — | — |
| 2025-11-26 | FELD, MICHAEL | EVP, CRO & Pres. Life Sciences | Sale | 419 | — | — |
| 2025-11-26 | DELOREFICE, CHRISTOPHER | EVP & Chief Financial Officer | Buy | 6,006 | — | — |
| 2025-11-26 | DELOREFICE, CHRISTOPHER | EVP & Chief Financial Officer | Sale | 4,245 | — | — |
| 2025-11-26 | BYRD, RICHARD | EVP & President Interventional | Buy | 6,447 | — | — |
| 2025-11-26 | BYRD, RICHARD | EVP & President Interventional | Buy | 2,385 | — | — |
| 2025-11-26 | BYRD, RICHARD | EVP & President Interventional | Sale | 1,719 | — | — |
| 2025-11-07 | SCOTT, BERTRAM L | Director | Sale | 217 | $176.58 | $38317.86 |
| 2025-11-04 | JONES, CHRISTOPHER IAN MONTAGUE | Director | Buy | 168 | $178.71 | $30023.28 |
| 2025-11-04 | BYINGTON, CARRIE L | Director | Buy | 34 | $178.71 | $6076.14 |
| 2025-10-27 | FELD, MICHAEL | EVP & President, Life Sciences | Sale | 57 | $186.01 | $10602.57 |
| 2025-09-26 | FELD, MICHAEL | EVP & President, Life Sciences | Sale | 58 | $181.03 | $10499.74 |
| 2025-09-10 | FRASER, CLAIRE | Director | Sale | 917 | $187.50 | $171937.50 |
| 2025-09-01 | DELOREFICE, CHRISTOPHER | EVP & Chief Financial Officer | Sale | 278 | — | — |
| 2025-09-01 | BYRD, RICHARD | EVP & President Interventional | Sale | 216 | — | — |
| 2025-08-22 | FELD, MICHAEL | EVP & President, Life Sciences | Sale | 57 | $197.99 | $11285.43 |
| 2025-08-20 | FELD, MICHAEL | EVP & President, Life Sciences | Sale | 773 | — | — |
| 2025-08-11 | HAYES, GREGORY | Director | Buy | 5,250 | $191.57 | $1.01M |
| 2025-08-08 | FRASER, CLAIRE | Director | Sale | 863 | $192.30 | $165954.90 |
Frequently asked questions
Are BDX insiders buying or selling?
Over the transactions on record, BDX insiders have been net buyers, with about $13.43M in stock sold across 49 sales, against 13 open-market purchases.
Does insider selling at BDX mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which BDX insiders are selling the most?
Recent selling is concentrated in a few names. POLEN, THOMAS E JR accounts for the largest share on record, with about $10.96M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.